Upstate Active Clinical Trials

Study Title:

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

What is the purpose of the study?

This randomized phase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.

Upstate Institutional Review Board (IRB) Number:

252337

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Sheila M Lemke, MD

ClinicalTrials.Gov ID:

NCT01275677

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Virginia M Schutt, CCRP
Phone: 315-464-8230
Email: schuttg@upstate.edu

Return to Previous Page || Search Again